Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus standard therapy in advanced solid tumors with neuroendocrine differentiation
ChiCTR2300069560Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of surufatinib in non-small cell lung cancer (NSCLC) and gastric adenocarcinoma with neuroendocrine differentiation (GA-NED) (2 cohorts), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: progression-free survival. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinoma with neuroendocrine differentiation (GA-NED)
Beyond the preview
Go deeper on ChiCTR2300069560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069560.